Invivo Partners
Overview
Invivo Partners is a Spanish venture capital firm that invests in early-stage life science companies, with a focus on advanced therapies, synthetic biology, and artificial intelligence.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Neumirna Therapeutics | Jan 2025 | Series A | Lead |
| Telomere Therapeutics | May 2021 | Seed | Lead |
| Corteria Pharmaceuticals | Sep 2023 | Series A | Co-investor |
| Signadori Bio | May 2026 | Seed | Co-investor |
| Gyala Therapeutics | Sep 2025 | Seed | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Invivo Partners based?
Invivo Partners is headquartered in Barcelona, Spain.
When was Invivo Partners founded?
Invivo Partners was founded in 2012.
How many portfolio companies does Invivo Partners have?
Invivo Partners has 13 portfolio companies in Caplight's dataset.
What are some companies in Invivo Partners's portfolio?
Portfolio companies visible on Caplight include Neumirna Therapeutics, Telomere Therapeutics, Corteria Pharmaceuticals, Signadori Bio, Gyala Therapeutics.
What was Invivo Partners's most recent investment shown here?
Invivo Partners's most recent investment in this portfolio sample was in Signadori Bio in 2026.
What sectors does Invivo Partners focus on?
Invivo Partners focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does Invivo Partners focus on?
Invivo Partners typically invests at the Early stage.
What is Invivo Partners's AUM?
Invivo Partners's assets under management are estimated between $162.0M and $280.8M.